The efficacy and safety of lubiprostone for constipation in cancer patients compared with non-cancer patients: A retrospective cohort study

Hikaru Sada, Makoto Kajizono, Souichiro Ushio, Satoru Esumi, Yoshihisa Kitamura, Toshiaki Sendo

Research output: Contribution to journalArticlepeer-review

Abstract

Lubiprostone is an effective drug for various types of constipation in patients without cancer; however, there is no report on its efficacy and safety in patients with cancer. Our purpose was to evaluate the efficacy and safety of lubiprostone for constipation in cancer patients. We retrospectively studied 124 patients (cancer, N=67) who were treated with lubiprostone for constipation in our hospital between June 2013 and May 2016. The number of bowel movements (BMs) increased in the both the cancer and non-cancer groups. The mean change in BM frequency did not differ between the two groups. Approximately 70% of patients in both groups had an initial BM within 24h after administration of lubiprostone. The most common lubiprostone-related adverse events in both groups were diarrhea (38.8 vs. 14%), and nausea (22.4 vs. 8.8%). No lubiprostone-related serious adverse events occurred. Discontinuation due to the side effects of lubiprostone was more frequent in cancer patients (p=0.023). Logistic regression analysis showed that the risk of discontinuation of lubiprostone in cancer patients was high in patients with a body-mass index (BMI) <22, and low in patients using opioids and magnesium oxide dosage ≥1000mg/d. Our study showed that while lubiprostone was as effective in cancer patients as in non-cancer patients, in cancer patients it was associated with a high incidence of diarrhea and nausea side effects and warranted caution, especially in patients with a low BMI.

Original languageEnglish
Pages (from-to)1699-1706
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume43
Issue number11
DOIs
Publication statusPublished - Nov 1 2020

Keywords

  • Body-mass index
  • Cancer
  • Constipation
  • Lubiprostone
  • Magnesium oxide
  • Opioid

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'The efficacy and safety of lubiprostone for constipation in cancer patients compared with non-cancer patients: A retrospective cohort study'. Together they form a unique fingerprint.

Cite this